More on SPPI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-166.7% Growth)
- Ratings (6.7 Score)
- Holders
- Dividends
- FDA

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (5/6/16 *Est.)
- PDUFA (5/9/2016)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SPPI Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 139.74M
Marketable securities 245K
Accounts receivable, net of allowance for doubtful accounts of $630 and $339, respectively 30.38M
Inventories, net 4.18M
Prepaid expenses and other current assets
Total current assets 191.32M
Investments
Property and equipment, net 918K
Intangible assets, net
Other assets 20.68M
TOTAL ASSETS 421.22M
Current Liabilities:
Accounts payable and other accrued obligations 56.54M
Accrued compensation and related expenses
Deferred revenue 6.13M
Common stock warrant liability
Accrued drug development costs 259K
Total current liabilities 76.34M
Capital lease obligations
Deferred revenue and other credits--less current portion
Zevalin related contingent obligations 7.44M
Total liabilities 208.36M
Commitments and contingencies 0
Stockholders' Equity:
Preferred stock value 0
Common stock, $0.001 par value--175,000,000 shares authorized; 52,947,221 and 51,459,284 issued and outstanding at June 30, 2011 and December 31, 2010, respectively 68K
Additional paid-in capital 552.11M
Accumulated other comprehensive loss -5.32M
Accumulated deficit -334.12M
Total stockholders' equity 212.86M
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 421.22M
Series E convertible preferred stock
Stockholders' Equity:
Preferred stock value 123K